No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
SGHT Sight Sciences
- 8.240
- +0.260+3.26%
Close Jul 23 16:00 ET
409.99MMarket Cap-7357P/E (TTM)
8.450High7.920Low201.99KVolume7.930Open7.980Pre Close1.66MTurnover0.69%Turnover RatioLossP/E (Static)49.76MShares9.30852wk High3.75P/B241.79MFloat Cap1.04052wk Low--Dividend TTM29.34MShs Float42.570Historical High--Div YieldTTM6.64%Amplitude1.040Historical Low8.209Avg Price1Lot Size
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Sight Sciences, Inc.'s (NASDAQ:SGHT) 25% Price Boost Is Out Of Tune With Revenues
Press Release: Sight Sciences to Report Second Quarter Financial Results on August 1, 2024
Express News | Morgan Stanley Maintains Equal-Weight on Sight Sciences, Raises Price Target to $6.5
Express News | Sight Sciences Inc : Morgan Stanley Raises Target Price to $6.50 From $5.40
Morgan Stanley Raises Price Target on Sight Sciences to $6.50 From $5.40, Keeps Equalweight Rating
Sight Sciences Up 21%, Insider Buyers Are Up 147%
Comments
$Sight Sciences(SGHT.US$
Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis
Sight Sciences announced the publication of twelve-month results from the SAHARA trial, showing clinically meaningful improvements in dry eye disease for patients who switched from Restasis to the TearCare treatment. Phase 2 of the trial included 163 patients who had used Rest...
Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis
Sight Sciences announced the publication of twelve-month results from the SAHARA trial, showing clinically meaningful improvements in dry eye disease for patients who switched from Restasis to the TearCare treatment. Phase 2 of the trial included 163 patients who had used Rest...
1
$Sight Sciences(SGHT.US$
NEWS
Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma
Sight Sciences, Inc. (Nasdaq: SGHT) announces results of a large-scale MIGS study comparing three leading technologies in glaucoma patients. OMNI technology shows significant IOP and...
NEWS
Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma
Sight Sciences, Inc. (Nasdaq: SGHT) announces results of a large-scale MIGS study comparing three leading technologies in glaucoma patients. OMNI technology shows significant IOP and...
Revolutionizing Glaucoma and Dry Eye Treatment: Insights from Sight Sciences' Groundbreaking Clinical Trials.
In the realm of ophthalmology, groundbreaking advancements are not just welcomed; they are necessary. As we navigate through the complexities of eye diseases, companies like Sight Sciences are leading the charge with innovative solutions that promise not only relief but also a renewed hope for millions globally. Rec...
In the realm of ophthalmology, groundbreaking advancements are not just welcomed; they are necessary. As we navigate through the complexities of eye diseases, companies like Sight Sciences are leading the charge with innovative solutions that promise not only relief but also a renewed hope for millions globally. Rec...
Sight Sciences' high P/S ratio may be precarious given forecasted revenue declines, posing the risk of a future drop in share prices despite recent gains.
$Sight Sciences(SGHT.US$ crazy day, what is going on?!
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg